Why InterVene’s first 30 Recana cases could reshape treatment for venous in-stent restenosis
InterVene has completed 30 Recana cases, raising new questions about venous ISR treatment, adoption, and launch strategy. Read the full analysis.
Medical Devices & Diagnostics
Pharma & Biotech
Why Meiji Seika Pharma is using Singapore to scale its ASEAN vaccine and pharma strategy
Meiji Seika Pharma has launched Meiji Pharma Asia in Singapore. Read what this ASEAN expansion could change for vaccines and regional pharma growth.
Pharma & Biotech
Why the latest Merakris Therapeutics data may sharpen industry focus on refractory wound healing
Read why Merakris Therapeutics’ MTX-001 data may sharpen industry focus on refractory wound healing and reshape the late-stage wound care outlook.
Pharma & Biotech
Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears
electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.
Pharma & Biotech
Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
Pharma & Biotech
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.
Pharma & Biotech
Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself
Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.
Pharma & Biotech
Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.
Pharma & Biotech
Can Currax and Peek make oral obesity treatment easier to access for self-funded employers?
Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.
Medical Devices & Diagnostics
Imbed Biosciences wins CMS HCPCS code for Microlyte PainGuard, but will billing clarity translate into wound care adoption?
Imbed Biosciences secured CMS HCPCS code A2040 for Microlyte PainGuard. Read what it changes for wound care adoption, billing, and reimbursement.